Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 400 participants.

Also called NCT07846579

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 400 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07846579
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07846579. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2028-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ceasing Alpha-blockers Early After Resection of the Prostate (The CLEAR Trial)
Acronym
CLEAR
Condition
Benign Prostatic Hyperplasia
Intervention (Drug)
Tamsulosin hydrochloride 0.2 mg
Intervention (Drug)
Placebo
Lead sponsor
Shanghai East Hospital (class: other)

Record details

Record id
cardio:ct-nct07846579
Content hash
3224d99b2bc7b4e49d7dd533910a912733177a4e570b88f7a2214cdfcdd77af3